
    
      Dilated cardiomyopathy secondary to chemotherapy accounts for approximately 1% of all dilated
      cardiomyopathies.

      Initial studies showed beneficial effect of the use of carvedilol for the prevention of
      chemotherapy-induced cardiomyopathy. This study has the objective to evaluate the
      effectiveness of carvedilol for the prevention of chemotherapy-induced cardiomyopathy. Will
      be selected 200 patients referred for chemotherapy that includes anthracyclines for breast
      cancer.These patients will be randomized to carvedilol or placebo and will have periodic
      assessment of cardiac function with echocardiography and biomarkers until complete
      chemotherapy and 24 months later.
    
  